Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 115 clinical trials
Azacitidine and Homoharringtonine in JMML

Juvenile myelomonocytic leukemia (JMML) has a poor prognosis in general, with hematopoietic stem cell transplant (HSCT) remaining the standard of care for cure. Azacitidine and homoharringtonine

refractory acute myeloid leukemia (aml)
myeloid leukemia
azacitidine
  • 0 views
  • 25 Jan, 2021
  • 1 location
Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS

This study will treat patients with previously untreated high grade myleodysplastic syndromes (MDS) with both omacetaxine mepesuccinate and azacitidine.

  • 4 views
  • 28 Jan, 2021
  • 1 location
A Study of ALX148 With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

This Phase 1/2 clinical study will evaluate ALX148 in combination with azacitidine for the treatment of patients with higher risk myelodysplastic syndrome (MDS).

  • 0 views
  • 16 Apr, 2021
  • 6 locations
Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia

treatment of relapsed/refractory acute myeloid leukemia in adult patients (intensive chemotherapy amsacrine-cytarabine or azacitidine according to investigator's willingness) results in a significant

  • 0 views
  • 25 Jan, 2021
  • 5 locations
Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML

high relapse rate and treatment-related complications. Azacitidine (AZA), a listed hypomethylating agent in China in 2018, is the only approved demethylating drug in the treatment of AML, following the

  • 0 views
  • 25 Jan, 2021
  • 2 locations
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)

The primary objective of this study is to evaluate the efficacy of magrolimab in combination with azacitidine compared to that of azacitidine plus placebo in previously untreated participants

remission
azacitidine
high risk myelodysplastic syndrome
  • 0 views
  • 08 May, 2021
  • 57 locations
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

The purpose of this study is to assess the safety, tolerability and clinical activity of the combination S65487 with azacitidine in patients with acute myeloid leukaemia.

  • 0 views
  • 13 May, 2021
  • 1 location
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS) Chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (AML)

The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared with single-agent azacitidine. (An event is

induction chemotherapy
chronic myelomonocytic leukemia
azacitidine
myeloid leukemia
leukemia
  • 341 views
  • 09 May, 2021
  • 320 locations
Triple Combination of Pevonedistat and Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy

The purpose of this study is to determine whether the combination of pevonedistat + venetoclax + azacitidine improves event-free survival (EFS) compared with venetoclax + azacitidine in patients

gilbert's syndrome
ejection fraction
hemolysis
ara-c
hydroxyurea
  • 2 views
  • 13 May, 2021
  • 59 locations
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Patients With CD123-Positive Acute Myeloid Leukemia

azacitidine and/or venetoclax in patients with relapsed and frontline CD123-positive AML, and antileukemia activity of IMGN632 when administered as monotherapy in patients with MRD+ AML after frontline

remission
ejection fraction
acute promyelocytic leukemia
graft versus host disease
hydroxyurea
  • 3 views
  • 18 Mar, 2021
  • 21 locations